Chemotherapy after PD‐1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics

Checkpoint inhibitors (CPIs) are routinely employed in relapsed/refractory classical Hodgkin lymphoma. Nonetheless, persistent long‐term responses are uncommon, and one‐third of patients are refractory. Several reports have suggested that treatment with CPIs may re‐sensitize patients to chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Calabretta, Eleonora, Guidetti, Anna, Ricci, Francesca, Di Trani, Martina, Monfrini, Chiara, Magagnoli, Massimo, Bramanti, Stefania, Maspero, Davide, Morello, Lucia, Merli, Michele, Di Rocco, Alice, Graudenzi, Alex, Derenzini, Enrico, Antoniotti, Marco, Rossi, Davide, Corradini, Paolo, Santoro, Armando, Carlo‐Stella, Carmelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematological Malignancy‐clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321573/
https://www.ncbi.nlm.nih.gov/pubmed/35468225
http://dx.doi.org/10.1111/bjh.18183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321573/
https://www.ncbi.nlm.nih.gov/pubmed/35468225
http://dx.doi.org/10.1111/bjh.18183

Ejemplares similares